Fulcrum Therapeutics Inc (FULC)
2.97
-0.02
(-0.67%)
USD |
NASDAQ |
Nov 21, 16:00
2.97
0.00 (0.00%)
After-Hours: 20:00
Fulcrum Therapeutics Enterprise Value: -97.04M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -97.04M |
| November 20, 2024 | -95.96M |
| November 19, 2024 | -94.88M |
| November 18, 2024 | -93.80M |
| November 15, 2024 | -95.15M |
| November 14, 2024 | -78.16M |
| November 13, 2024 | -65.21M |
| November 12, 2024 | -60.90M |
| November 11, 2024 | -60.90M |
| November 08, 2024 | -68.99M |
| November 07, 2024 | -69.53M |
| November 06, 2024 | -72.22M |
| November 05, 2024 | -78.16M |
| November 04, 2024 | -81.39M |
| November 01, 2024 | -84.09M |
| October 31, 2024 | -86.79M |
| October 30, 2024 | -82.47M |
| October 29, 2024 | -82.47M |
| October 28, 2024 | -82.47M |
| October 25, 2024 | -85.17M |
| October 24, 2024 | -82.47M |
| October 23, 2024 | -81.93M |
| October 22, 2024 | -74.38M |
| October 21, 2024 | -67.91M |
| October 18, 2024 | -67.91M |
| Date | Value |
|---|---|
| October 17, 2024 | -65.75M |
| October 16, 2024 | -61.98M |
| October 15, 2024 | -59.82M |
| October 14, 2024 | -64.67M |
| October 11, 2024 | -69.53M |
| October 10, 2024 | -80.85M |
| October 09, 2024 | -73.30M |
| October 08, 2024 | -66.29M |
| October 07, 2024 | -64.67M |
| October 04, 2024 | -51.19M |
| October 03, 2024 | -59.55M |
| October 02, 2024 | -48.49M |
| October 01, 2024 | -63.05M |
| September 30, 2024 | -64.67M |
| September 27, 2024 | -38.53M |
| September 26, 2024 | -24.17M |
| September 25, 2024 | -57.25M |
| September 24, 2024 | -73.47M |
| September 23, 2024 | -74.10M |
| September 20, 2024 | -64.11M |
| September 19, 2024 | -58.50M |
| September 18, 2024 | -59.12M |
| September 17, 2024 | -56.00M |
| September 16, 2024 | -75.34M |
| September 13, 2024 | -75.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-158.26M
Minimum
Apr 12 2023
1.122B
Maximum
Sep 20 2021
222.67M
Average
205.71M
Median
Aug 26 2022
Enterprise Value Benchmarks
| Bioventus Inc | 1.131B |
| Arcturus Therapeutics Holdings Inc | 225.20M |
| Johnson & Johnson | 389.84B |
| Pfizer Inc | 199.35B |
| Tenon Medical Inc | 2.839M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.70M |
| Total Expenses (Quarterly) | 23.06M |
| EPS Diluted (Quarterly) | -0.35 |
| Earnings Yield | -10.44% |
| Normalized Earnings Yield | -11.78 |